Top Markets
Coin of the day
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Rang in Aktien #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Aktienkurs
$2.65
Zuletzt synchronisiert: 2024-04-03
Marktkapitalisierung
$115.71M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Kinnate Biopharma Inc. (KNTE)

Kategorie

Aktien-Split-Historie für Kinnate Biopharma Inc. (KNTE)
Die Aktie Kinnate Biopharma Inc. (Symbol: KNTE) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 23, 2026 statt.
Eine KNTE-Aktie, die vor dem Aug 23, 2026 gekauft wurde, entspricht heute 0 KNTE-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH